Related Experiment Video
Updated: Feb 13, 2026
06:14
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
7.5K
Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery
Xinping Fu1, Tomasz Benedyk1, Shaun Xiaoliu Zhang1
1Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Molecular Therapy. Oncology
|February 12, 2026
Summary
FusOn-SD, a modified oncolytic virus, overcomes challenges in systemic cancer virotherapy. It evades immune clearance and antibody neutralization, showing promise for treating metastatic tumors.
Area of Science:
- Oncolytic virotherapy
- Cancer immunotherapy
- Viral oncology
Background:
- Oncolytic virotherapy (OV) utilizes viruses to target and destroy cancer cells, stimulating anti-tumor immunity.
- Current OV treatments are limited by intratumoral administration, hindering treatment of metastatic or inaccessible tumors.
- Systemic delivery faces challenges from rapid clearance by the mononuclear phagocyte system (MPS) and neutralization by antiviral antibodies.
Purpose of the Study:
- To develop an enhanced oncolytic virus, FusOn-SD, for effective systemic delivery.
- To engineer FusOn-SD to evade immune clearance and antibody neutralization for improved efficacy.
- To evaluate the potential of FusOn-SD in treating metastatic cancer via systemic administration.
Main Methods:
- Genetic modification of FusOn-H2 to incorporate the CD47 extracellular domain (ECD) for MPS evasion.
- Adaptive modification through serial passaging in immune sera to increase resistance to neutralizing antibodies.
- Preclinical evaluation of FusOn-SD's biodistribution, immune evasion, and oncolytic potency following systemic administration.
Main Results:
- FusOn-SD demonstrated efficient tumor targeting after systemic administration.
- The engineered virus exhibited enhanced immune evasion capabilities.
- FusOn-SD showed increased oncolytic potency compared to unmodified viruses.
- Preclinical studies confirmed FusOn-SD's potential for systemic cancer virotherapy.
Conclusions:
- FusOn-SD represents a significant advancement in oncolytic virotherapy, overcoming key barriers to systemic delivery.
- This enhanced virus holds promise for treating metastatic and inaccessible tumors, expanding the clinical applications of OV.
- FusOn-SD could transform oncolytic virotherapy into a viable systemic treatment option for advanced cancers.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
3
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
3
01:23Ophthalmic Drug Delivery Systems
1
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
1
01:21Intrauterine Drug Delivery Systems
1
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
1
01:27Drug Delivery Systems: Different Types
1
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
1
01:26Oral Drug Delivery Systems: Continuous-Release Systems
1
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
1
01:11Oral Drug Delivery Systems: Delayed-Release Systems
2
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
2